Human papillomavirus, vaccines and women's health: questions and cautions

Lippman, Abby; Melnychuk, Ryan; Shimmin, Carolyn; Boscoe, Madeline

doi:10.1503/cmaj.070944

Cited by 68 publications

(58 citation statements)

References 4 publications

(2 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In Canada, concerns over lobbying were more subdued. The cost effectiveness of allocating public funds for school-based immunization programs for girls in Grade 8 starting in September 2007 in various provinces was debated due to the lack of long-term data from clinical trials (Lippman et al, 2007). In both countries, the involvement of many stakeholders, each with a distinct objective, and the sensitive nature of vaccination programs for a STI being targeted to young girls, contributed to the mixed reactions from the public and health officials alike.…”

Section: Introductionmentioning

confidence: 99%

Risk Messages About HPV, Cervical Cancer, and the HPV Vaccine Gardasil: A Content Analysis of Canadian and U.S. National Newspaper Articles

Abdelmutti

Hoffman‐Goetz

2009

Women & Health

View full text Add to dashboard Cite

The human papillomavirus vaccine (Gardasil) is a significant advancement in women's health. We compared the reporting of fearinducing messages about human papillomavirus, cervical cancer, and the human papillomavirus vaccine in Canadian and U.S. national newspapers between January 2006 and December 2007. Significant differences between countries were found in the number of articles containing fear messages about human papillomavirus, cervical cancer, and the human papillomavirus vaccine. Educational level of readability was higher than recommended for the public, and the emotional tone of the articles became progressively negative over time. Our findings suggest that public discussion of some elements of the human papillomavirus vaccine message that could cause alarm or worry for women may need to be addressed within political and cultural contexts.

show abstract

Section: Introductionmentioning

confidence: 99%

Risk Messages About HPV, Cervical Cancer, and the HPV Vaccine Gardasil: A Content Analysis of Canadian and U.S. National Newspaper Articles

Abdelmutti

Hoffman‐Goetz

2009

Women & Health

View full text Add to dashboard Cite

show abstract

“…6 Despite the popularity of large-scale immunization programs, HPV vaccination has faced a great deal of controversy regarding unanswered questions about the real-world effects of this vaccine. 7,8 A major topic of public debate has been the possibility that HPV vaccination might lead to sexual disinhibition, 9 that is, that receipt of the vaccine might give women and girls a false sense of protection against all sexually transmitted infections and that this false sense of protection might lead them to engage in more risky sexual behaviours than they would otherwise (e.g., be more promiscuous or neglect to use condoms). Increases in these risky behaviours could have important clinical consequences, including increased risk of pregnancy and sexually transmitted infections.…”

mentioning

confidence: 99%

Effect of human papillomavirus (HPV) vaccination on clinical indicators of sexual behaviour among adolescent girls: the Ontario Grade 8 HPV Vaccine Cohort Study

Smith

Kaufman

Strumpf

et al. 2014

CMAJ

106

View full text Add to dashboard Cite

show abstract

“…The technology involved in the vaccine requires a large investment; it is the most expensive vaccine proposed for mass use. The cost is estimated between US $300 and US $400 for three doses [31]. Based on the lessons learned with the Hepatitis B vaccine, which is available today for children in 89% of the countries in the world, including the poorest countries, mass vaccination on a global scale may only be possible after a drastic reduction in the price of the vaccine [32].…”

Section: Strategiesmentioning

confidence: 99%

Cost-Effectiveness of Primary and Secondary Prevention Strategies for Cervical Cancer in Brazil: A Systematic Review

Fonseca¹

2013

Gynecol Obstet

View full text Add to dashboard Cite

BackgroundAlthough Cervical Cancer (CC) can be effectively prevented, almost 500,000 new cases are diagnosed each year worldwide [1]. The global reduction in the incidence and mortality from CC over the last four decades did not occur in a homogeneous manner; it was concentrated in the developed countries that were able to implement solid and effective population screening programs [2].In Brazil, organizational and financial difficulties have compromised the quality of prevention programs based on Oncotic Cytology (OC), and they have not succeeded in controlling the disease ; approximately 17,500 new cases of CC are expected in 2013 [3][4][5]. It is the second most common type of neoplasia in women (excluding non-melanoma skin cancer), and it is the type of neoplasia that claims the most lives of young women (15 to 44 years of age) [1].These difficulties, which are associated with the inherent limitations of the OC technique, have led many researchers to seek alternative or supplementary techniques for OC for CC screening, such as the hybrid capture test (HPV-DNA), and, more recently, to prepare vaccines against the most carcinogenic genotypes of HPV. These new technologies exhibit better performance and/or effectiveness; however, they would result in higher costs if they were incorporated into Brazil's prevention strategy.Because of the universal increase in healthcare costs and the growing constraints imposed by the scarcity of resources, there is a greater need to justify the use of a new technique by considering its cost-effectiveness ratio [6]. To handle this growing demand, economic analysis tools can be applied to new healthcare technologies to support decision-making in public health that aims for rational and efficient use of available resources [7,8].Among the methods of economic evaluation, cost-effectiveness analyses have received special attention [7]. Markov models have been widely used to evaluate new technologies and to compare healthcare strategies around the world. In comparing two strategies, the Markovian model provides the Incremental Cost-Effectiveness Ratio (ICER) as the primary result [8]. This ratio shows the additional cost required to save 1 year of life (adjusted or not by quality of life) using one strategy compared to a baseline strategy. The World Health Organization stipulates that a strategy is considered cost-effective if the AbstractBackground: Although Cervical Cancer (CC) can be effectively prevented, it is still a serious public health problem, especially in developing countries. In Brazil, almost 18,000 new cases are expected in 2013, and it is the type of neoplasia that claims the most lives of young women. New secondary prevention strategies (such as the HPV-DNA test) and primary prevention strategies (vaccination against HPV) have been developed. However, applying these strategies to large populations is costly, and their use is limited in Brazil. Because financial resources are scarce in Brazilian scenario, studies about the economic implications of the new preventativ...

show abstract

Human papillomavirus, vaccines and women's health: questions and cautions

Cited by 68 publications

References 4 publications

Risk Messages About HPV, Cervical Cancer, and the HPV Vaccine Gardasil: A Content Analysis of Canadian and U.S. National Newspaper Articles

Risk Messages About HPV, Cervical Cancer, and the HPV Vaccine Gardasil: A Content Analysis of Canadian and U.S. National Newspaper Articles

Effect of human papillomavirus (HPV) vaccination on clinical indicators of sexual behaviour among adolescent girls: the Ontario Grade 8 HPV Vaccine Cohort Study

Cost-Effectiveness of Primary and Secondary Prevention Strategies for Cervical Cancer in Brazil: A Systematic Review

Contact Info

Product

Resources

About